AXJ Axm Pharma

Company To Submit Plan To Comply With AMEX Listing Requirements LAS VEGAS, Nov. 30 /PRNewswire-FirstCall/ -- AXM Pharma, Inc. (AMEX:AXJ), a manufacturer of proprietary and generic pharmaceutical and nutraceutical products for the Chinese and other Asian markets, announced today that it has filed its Form 10-Q for the third quarter ended September 30, 2005. Prior to the filing the Company was advised by the American Stock Exchange (the "Exchange") that its failure to timely file its quarterly report on Form 10-Q for the period ended September 30, 2005 (the "10-Q") is a material violation of the Company's listing agreement with the Exchange. The Exchange has given the Company until December 9, 2005 to submit a plan to bring the Company into compliance with the listing requirements. The Company intends to submit a compliance plan prior to December 9, 2005. If the plan submitted by the Company is not accepted by the Exchange, or if the Company fails to comply with the plan, it could be subject to delisting proceedings. AXM Pharma Inc., through its wholly owned subsidiary, AXM Pharma Shenyang, Inc ("AXM Shenyang"), is a manufacturer of proprietary and generic pharmaceutical products, which include injectables, capsules, tablets, liquids and medicated skin products for export and domestic Chinese sales. AXM Shenyang is a Wholly Foreign Owned Enterprise ("WFOE") under the laws of the People's Republic of China and is located in the City of Shenyang, in the Province of Liaoning, China. AXM Shenyang has an operating history of approximately 10 years. For additional information on AXM Pharma Inc, please visit http://www.axmpharma.com/ or call the Company's investor relations firm, the MKR Group, at 818-556-3700. Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this news release include certain predictions and projections that may be considered forward-looking statements under securities law, including the statements regarding the Company's opportunities for future growth. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, obtaining regulatory approvals to market the Company's products, the uncertainties associated with distributing products in a developing country such as China, the availability of cash to meet near term requirements as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products and prices. With respect to AXM, except for the historical information contained herein, the matters discussed in this news release are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, AXM's extremely limited operating history, uncertainties related to the Company's access to additional capital, competition and dependence on key management. DATASOURCE: AXM Pharma, Inc. CONTACT: Charles Messman or Todd Kehrli both of MKR Group, LLC for AXM Pharma Inc., +1-818-556-3700, or Web site: http://www.axmpharma.com/

Copyright